FDA panel rejects Sunrise eye laser after concerns that benefits of treatment wear off
This article was originally published in Clinica
Advisors to the US FDA last week recommended that an application by Sunrise Technologies for approval of its LTK laser for treating low to moderate farsightedness be rejected. The panel was concerned that the initial improvement in the vision of these patients seemed to wear off two years later.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.